{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:22:23Z","timestamp":1778080943264,"version":"3.51.4"},"reference-count":7,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:p>This Viewpoint explores the ethical questions involved in the design and conduct of the RDD trial among individuals stopping medications for opioid use disorder.<\/jats:p>","DOI":"10.1001\/jamapsychiatry.2026.0246","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:30:40Z","timestamp":1773847840000},"page":"439","source":"Crossref","is-referenced-by-count":0,"title":["Research Ethics in Stopping Opioid Use Disorder Medication"],"prefix":"10.1001","volume":"83","author":[{"given":"Roger D.","family":"Weiss","sequence":"first","affiliation":[{"name":"Division of Alcohol, Drugs and Addiction, McLean Hospital, Belmont, Massachusetts"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott E.","family":"Provost","sequence":"additional","affiliation":[{"name":"Division of Alcohol, Drugs and Addiction, McLean Hospital, Belmont, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"13","key":"yvp260003r1","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMp2505377","article-title":"Goals for opioid use disorder medications - protection, remission, and recovery.","volume":"393","author":"McLellan","year":"2025","journal-title":"N Engl J Med"},{"key":"yvp260003r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2024.107543","article-title":"Discontinuation of medication treatment for opioid use disorder after a successful course: the discontinuation phase of the CTN-0100 (RDD) trial.","volume":"142","author":"Shulman","year":"2024","journal-title":"Contemp Clin Trials"},{"issue":"12","key":"yvp260003r3","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"yvp260003r4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.drugalcdep.2017.03.013","article-title":"Effectiveness of treatment for opioid use disorder: a national, five-year, prospective, observational study in England.","volume":"176","author":"Eastwood","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"yvp260003r5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial.","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"issue":"11","key":"yvp260003r6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030912","article-title":"Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction).","volume":"9","author":"Moncrieff","year":"2019","journal-title":"BMJ Open"},{"issue":"9","key":"yvp260003r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.34168","article-title":"Prescribing characteristics associated with opioid overdose following buprenorphine taper.","volume":"5","author":"Bozinoff","year":"2022","journal-title":"JAMA Netw Open"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2846476\/jamapsychiatry_weiss_2026_vp_260003_1777052903.24919.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:00:31Z","timestamp":1778079631000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2846476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2026.0246","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}